Background. Human immunodeficiency virus type 1 (HIV-1) uses the CD4 receptor and a coreceptor to gain cell entry. Coreceptor usage is mainly determined by the V3 loop of gp120. Therefore, coreceptor usage is currently inferred from the genotype on the basis of V3 alone. However, several mutations outside V3 have been repeatedly reported to influence coreceptor usage. In this study, the impact of the V2 loop on coreceptor usage prediction was analyzed.
The infection of human cells by human immunodeficiency virus (HIV) is mediated through the CD4 receptor and a second coreceptor. Several different coreceptors have been described from experiments performed in vitro. Only 2 of them have been shown to be relevant in vivo: CCR5 and CXCR4 [1] [2] [3] [4] [5] [6] . A virus is called an R5 virus if it can only use CCR5, whereas it is called an X4 virus if it only uses CXCR4 or a dualtropic (R5X4) virus if it can infect cells through both coreceptors. Viral quasispecies containing mixed pop- United States and Europe in 2007, and another-vicriviroc (Schering Plough)-is undergoing phase 3 clinical trials. Because these drugs are only effective against R5 viruses and do not inhibit CXCR4-using viruses, a tropism test is mandatory before administration.
The most widely used test measuring viral tropism is the Monogram Trofile tropism assay (Monogram Biosciences) [20] . It is a recombinant phenotypic assay that uses replication-defective viruses. It has been used in all clinical trials and has therefore become the de facto gold standard for measuring coreceptor tropism. Several other phenotypic assays have been developed [21, 22] .
Phenotypic approaches for tropism determination are precise and reproducible, but they share substantial drawbacks with their counterparts in resistance testing: they are expensive, have slow turnaround times, and can only be performed by a small number of laboratories [23, 24] . As for resistance testing, genotypic approaches provide an alternative. These are faster and cheaper and yield good results on the basis of clonal data [25] . When used to determine tropism on clinically derived isolates, however, they have previously appeared to perform much worse than phenotypic approaches [25, 26] . A noteworthy limitation is that common prediction methods are based on only the third hypervariable loop of gp120 (V3). Although this short region of about 35 residues is known to be the major determinant of coreceptor usage [27] [28] [29] [30] , mutations in the bridging sheet [31] [32] [33] [34] [35] [36] [37] and gp41 [38] have been correlated with tropism. So far, however, except for a study by Prosperi et al [35] with additional patient features and mutations outside V3, whether the incorporation of these mutations can improve prediction methods has not been evaluated. In this study, we address this question by analyzing the V2 loop, which has been reported repeatedly to be responsible for tropism switches [32] [33] [34] in conjunction with V3 sequences.
MATERIALS AND METHODS
Data sets. Three distinct data sets of different character were used. The first (clonal data set) included all samples of the Los Alamos HIV Sequence Database (http://www.hiv.lanl.gov/ content/sequence/HIV/mainpage.html; accessed July 2007) that had sequence information from the V2 and V3 loops of the envelope protein gp120 as well as an experimentally determined phenotype. The data set consists of 916 sequences from 312 patients. In fact, the data set is mostly clonal; we could confirm that ∼85% of the samples are indeed clonal. However, restricting the analysis to the subset of clonal samples showed only little effect.
The second data set (therapy-naive data set) contained 268 samples from a subset of therapy-naive patients in the welldescribed British Columbia HAART Observational Medical Evaluation and Research (HOMER) cohort [39] (HAART, highly active antiretroviral therapy). The cohort consists of HIV-positive, antiretroviral-naive adults who started triple antiretroviral therapy through the British Columbia Drug Treatment Program between August 1996 and September 1999. Samples used in this study were the latest ones collected in the 180 days prior to therapy initiation [39] . Coreceptor usage was determined by the original Trofile assay.
The third data set (therapy-experienced data set) consisted of isolates from 64 therapy-experienced patients that were screened with the original Trofile assay [20] for maraviroc administration. This data set was collected at the Institute for Virology of the University of Cologne (Cologne, Germany).
Sequences are available in GenBank under the following accession numbers: HM176666-HM176793, HM211408-HM211675, and EF637088-EF638008. For specific subsets, see the Appendix, which appears only in the online version of the Journal.
Determination of envelope sequences. Sequence variation of V2 and V3 was determined by population sequencing. Isolates from patients in the therapy-naive data set were genotyped as described elsewhere [10] . Viral RNA of samples collected for the therapy-experienced data set was isolated from plasma by using the MagNA Pure compact nucleic acid isolation kit (Roche Applied Science) according to manufacturer's protocol. Reverse transcription and polymerase chain reaction (PCR) were performed using the OneStep reverse-transcription PCR kit (Qiagen) with the following primers: V3F, 5 -AGAGCAGA-ATTCAGTGGCAATGAGAGTGA-3 (nucleotides 6202-6222); V3R, 5 -AGTGCTTCCTGCTGCTCCYAAGAACCC-3 (nucleotides 7785-7759). This was followed by nested PCR with HotStartTaq (Qiagen) with the following primers: V3-1, 5 -TGGGATCAAAGCCTAAAGCCATGTG-3 (nucleotides 6558-6582); V3-5, 5 -AAAATTCCCCTCCACAATTA-3 (nucleotides 7371-7352). PCR products were purified using a QIAquick spin PCR purification kit. The sequence reaction was performed with the following primers: V3-1; V3-2, 5 -CAGTACAAT-GYACACATGG-3 (nucleotides 6955-6973); V3-3, 5 -CCA-TGTGTRCATTGTACTG-3 (nucleotides 6955-6937); V3-4, 5 -GTACAATGTACACATGGAAT-3 (nucleotides 6957-6976); V3-5; and the ABI reaction mix. Extension products were purified using MultiScreen purification plates (Millipore) and Sephadex G-50 superfine filter (Amersham Biosciences) and were analyzed on an ABI 3130 Avant capillary sequencer. Obtained sequences were assembled and edited using Seqman software (version 7; DNAstar).
Sequence alignment and encoding. Multiple sequence alignments of the V2 and V3 loop sequences in the clonal data set were generated with the ClustalW program [40] . These profiles allow for possible insertions and deletions through several gap columns inserted before positions 165 and 189 (relative to reference strain HXB2) ( Figure 1 ). V2 and V3 sequences of all 3 data sets were then sequentially aligned to the respective profiles. Sequences were encoded with a canonical indicator representation in which each position in the aligned sequence is defined by a vector of 21 bits. Each component in this vector indicates the presence or absence of a specific amino acid (or gap) at this specific position in the aligned sequence. Data analysis, model generation, and evaluation. Prediction models were trained with support vector machines (SVMs) by use of the SVM light software package [41] . SVMs are supervised learning methods that are used for classification and regression. They construct a hyperplane in a highdimensional Euclidean space that optimally separates training data into 2 categories. The hyperplane is then used to classify new unseen data. Linear kernels were used for classification because previous studies showed that nonlinear kernels do not improve prediction quality for simple encodings [42] . The cost factor c was optimized with an internal grid search within a range of 10 Ϫ6 to 10.
All analyses on the clonal data set were repeated 10 times. In every replicate, at most 1 R5 sequence and 1 dual-mixed sequence per patient was randomly chosen. This was done to minimize potential bias due to overrepresented patients with many (similar) sequences. Prediction performances were assessed using 10-fold cross-validation on the clonal data set and with independent data sets from clinically derived samples.
Models containing the V2 loop were always trained and evaluated on the same set of samples as those for models that used only V3 in order to afford direct comparisons between the 2 types of models. Furthermore, the performance of the 11/25 rule [43] was computed. The 11/25 rule predicts a virus to be dual-mixed if a positively charged residue is found at position 11 and/or 25 of the V3 loop.
Statistical analysis was performed using the statistical programming language R [44] and the R package ROCR [45] . For performance assessment, the area under the receiver operating characteristic (ROC) curve (AUC), sensitivity, and specificity were computed. The statistical significance of different AUCs was assessed using the approach described by DeLong et al [46] . Sequence analysis. Sequences from the clonal data set were used to analyze every mutation at every position within V2 and V3 with the Fisher exact test. Positions 31-51 (185-189 in HXB2) in the sequence profile of V2 could not be aligned properly because of extensive length polymorphism in this part of V2. Because we could not guarantee reasonable alignments there, we did not use this length-polymorphic part of V2 (hereafter the remaining positions are called the V2 stem) in the mutation analysis. Mutations had to be statistically significant ( ) in all 10 repetitions to be reported as predictive.
In addition, other properties independent of a correct align- ment are known determinants of coreceptor usage (eg, the charge rule [47] takes the charge of the V3 loop into account). Therefore, residues of the length-polymorphic region of V2 could be taken into account here, too. For the V2 and V3 loop, as well as for the conserved and polymorphic parts of V2 alone, we analyzed the following features for differences between R5 and dual-mixed viruses: number of positively or negatively charged residues, overall charge, number of N-glycosylation sites, and length of the region. Statistical significance was assessed using the Student t test.
RESULTS
Impact of specific mutations on coreceptor usage. Several mutations within V2 were statistically significant for 1 of the phenotypes. Tables 1 and 2 show the results based on the clonal data set. Displayed frequencies are computed from the whole data set.
Differences between R5 and dual-mixed isolates within V2 are not as profound as those in V3 (see also [25] ). In most cases, the respective mutations within V2 occur in R5 isolates as well as in dual-mixed isolates, and only trends between the 2 groups, but not large differences, can be found for individual mutations. However, there are also mutations that are relatively specific for 1 phenotype (eg, V169T or S195H).
Impact of position-independent features on coreceptor usage. Several position-independent features were statistically significantly different between the 2 phenotypes (see Table 3 ). As expected, the differences between the number of positively and negatively charged residues, the number of N-glycosylation sites, and the charge of the V3 loop were statistically significant. Within V2, the number of negatively charged residues and the overall charge were statistically significantly different. Surprisingly, we did not find these differences in the V2 stem but within the highly polymorphic region. Although only the number of Nglycosylation sites differed statistically significantly within the V2 stem, the number of positively and negatively charged residues, the overall charge, and the length of the polymorphic region were statistically significantly different.
Comparison of prediction methods. The results of the mutation analysis and the differences between position-independent features suggested including the V2 loop in prediction methods. Therefore, prediction methods that used V2 alone, V3 alone, or both loops together were generated and validated in cross-validation studies. In each cross-validation analysis, the pool of training and test samples was the same for all 3 predictors. Figure 2 shows the ROC curves of the 3 different prediction methods. As demonstrated, models trained solely on V2 were clearly outperformed by the other 2 models and the 11/25 rule. At a specificity of 90%, on average only 34.6% of the dualmixed isolates could be detected using the V2 loop alone. For comparison, the 11/25 rule found 66.7% of the dual-mixed isolates to have a specificity of 96.1%. Nevertheless, the AUC of 0.730 of the V2 predictor showed that predictions were not random and suggested a positive influence when used in combination with V3.
Prediction models trained on V3 were much better than V2 models and the 11/25 rule (Figure 2 ). The mean sensitivity was 85.3% at a specificity of 90%. The mean AUC was 0.914.
When testing prediction models incorporating both V2 and V3, the mean AUC increased to 0.933, which is statistically significantly higher than that of predictors that used either V2 ( ) or V3 ( ) alone. More obvious differences P ! .001 P p .002 were found by comparing the different predictors at high specificities common for published methods. At a fixed specificity of 90%, the combination of V2 and V3 showed an improvement in sensitivity of 4.5 percentage points over standard V3 models. Similar results were found at 96.1% specificity (that of the 11/ 25 rule). At this level, the improvement in sensitivity of the combined method over the V3 predictor increased to 5 percentage points.
Validation of data derived from clinical isolates. The results on the clonal data set were very good even for prediction methods trained on V3 alone. This is in line with the findings of previous studies, in which prediction methods showed comparable results on data sets collected from the Los Alamos HIV Sequence Database. However, the performance of these methods dramatically decreases when tested on clinically derived samples. In a study by Low et al [26] , in which different publicly available prediction methods were tested on the HOMER cohort, even the best methods showed sensitivities of only 50% at a 90% specificity. We therefore validated our results on a subset of the HOMER cohort for which V2 sequences were also available and on isolates from therapy-experienced patients that were collected at the Institute for Virology of the University of Cologne. This facilitates direct comparison with the findings of previous studies of isolates from therapy-naive patients (the HOMER data were also used in the study by Low et al [26] ) and in addition allows for analysis of differences between isolates from therapy-naive patients and those from therapy-experienced patients.
Prediction results of therapy-naive and therapy-experienced patient data. Prediction models that used V3 alone or in combination with V2 were trained on the complete clonal data set. Inputs comprised the raw sequence information, and position-independent features were found to be statistically significant. Cost factors used to train the SVMs were optimized for each method on their own (c of V3 alone, 0.1; c of both V2 and V3, 0.05). V2 models are not shown because of their inferiority in the cross-validation study.
Of the 268 samples available, 233 (86.9%) were phenotyped by the Trofile assay as R5 and 35 (13.1%) as dual-mixed [20] . Figure 3 shows the prediction results for the therapy-naive data. The dashed line displays the ROC curve for the method trained solely on V3, whereas the solid line displays that for the combined method. The X marks the performance of the 11/25 rule. Although the specificity of the 11/25 rule is very high (98.3%), the sensitivity is just 31.4%. This is in line with the results of Low et al [26] , in which the 11/25 rule showed 30.5% sensitivity and 93.4% specificity. The performance of the V3 predictor was similar to that in this study, too (in the study by Low et al [26] , the geno2pheno[coreceptor] tool was trained on a similar data set and also used SVMs). The ROC curve of the predictor that used V2 and V3 data shows that it performs better than the standard V3 method. Although these results are still not as good as the results on clonal data, the sensitivity of this method is higher at all specificities. For 90% specificity, it increases in sensitivity by 8.6 percentage points (62.8% vs 54.2%). In terms of overall performance, the AUC of the V3 predictor was 0.779, whereas the use of sequence information on both loops increased the AUC to 0.841.
In a final analysis, we tested the same predictors with the same parameter settings on isolates from therapy-experienced patients (Figure 4 ). It should be noted that, in contrast to the naive data set, this data set had equal numbers of R5 and dualmixed isolates, which indicates that the patients had a higher degree of disease progression.
Prediction performances on this data set were generally better than those of the HOMER data. Although the sensitivity of the 11/25 rule increased to 43.7%, the specificity decreased to 93.7%. The prediction model that used only V3 reached a sensitivity of 59.4% at 90% specificity, whereas the use of both loops increased the sensitivity at this specificity to 71.8%. Corresponding to the results from the therapy-naive data set, the AUC of the combined method (0.871) was better than that of the method that used V3 only (0.815).
We also compared our results with those of the most widely used online tools, geno2pheno[coreceptor] [23] and WebPSSM [43] . On the therapy-naive data set, the sensitivities of these were 48.9% and 38.3% respectively, whereas the specificities were 90.0% and 94.3%, respectively. On the therapy-experienced data set, both methods performed much better, with a sensitivity of 56.2% and specificities of 93.7% and 87.5%, respectively. In both cases, the combined method that used V2 and V3 sequence variation performed clearly better.
DISCUSSION
In this study, we have shown that several sequence positions outside V3 are associated with coreceptor usage. Although correlations with phenotype were generally much weaker than for mutations within V3, some mutations (eg, V169T or S195H) showed strong associations with CXCR4 usage, and we suggest using them in prediction models where practical. However, whether these mutations are responsible for a switch in phenotype is still unclear. They can also be gain-of-fitness mutations that compensate for fitness losses induced by mutations directly responsible for the switch (as discussed by Pastore et al [34] ).
Incorporation of V2 into prediction models enhanced the performance of standard V3 models on all tested data sets. Although the standard V3 model already performed very well on clonal data, the addition of the V2 loop substantially improved the method. This was true for the overall performance as measured by the AUC as well as for sensitivities at high specificities, which increased by 4.5-5 percentage points.
We also found several position-independent features that were statistically significantly different between R5 and dualmixed samples. Interestingly, most differences were found in the length polymorphism region. Insertions there seemed to be quite random, but the features that were found indicate that there is a higher-level pattern that does not necessarily rely on easily identifiable mutations. Another interesting observation is that the length of the V2 loop was not correlated with tropism, as was suggested by the findings of previous studies [48] .
Although predictions based on clonal data were quite accurate, prediction methods performed much worse when tested on clinically derived isolates. Here, we observed substantial losses in performance with all tested methods. Still, models that made use of the sequence variation of both loops always performed best and increased the sensitivity over that of standard V3 models. At a specificity of 90%, the increase amounted to ∼8 percentage points on isolates from therapy-naive patients and ∼12 percentage points on isolates from therapy-experienced patients. Although these results are still not satisfactory on clinically derived isolates (especially from therapy-naive patients), we clearly show that improvements in prediction outcome can be achieved when sequence information from other parts of gp120 are incorporated into prediction methods.
The reasons for performance losses on clinically derived data are probably manifold. One cause is certainly the inability of standard bulk sequencers to detect minority variants. For example, the dual-mixed phenotype from the Trofile assay could come from minor variants that are not picked up by standard sequencers. Therefore, new technologies such as 454-sequencing that are able to detect minority populations at very low sensitivity levels should further improve prediction outcome. Because these technologies generate clones instead of bulk sequences, their use should also minimize interpretation problems with samples containing viral strains of different V2 lengths, which are generally hard to interpret in electropherograms.
Although tropism of the clinical isolates used in this study was determined with the original Trofile assay, a new enhanced assay (Trofile ES) with better sensitivity to detect minority populations has become available. However, the specificity seems to be reduced such that results similar to those of the original Trofile assay can be achieved using a lower specificity cutoff [49] . Whether this also holds for predictions based on V2 and V3 should be addressed in the future.
Our study also has some shortcomings. As mentioned above, the large number of possible insertions in the V2 loop makes it very difficult if not impossible to obtain a perfect alignment. Although we have tried to optimize the alignment, different approaches might improve this in the future. In addition, although the data set from the Los Alamos HIV Sequence Database consists of more than 900 genotype-phenotype pairs, the number of pairs to be analyzed is much lower because of patients displaying several sequences. Last but not least, the quality of genotypes, as well as that of phenotypes, varies extensively because different assays have been used. All these points may induce some bias in our analysis, but on the other hand they prove the stability of the results. With high-quality data sets, the results should become even more pronounced in the future.
To further improve prediction models, we suggest that future prediction systems incorporate clinical features such as CD4 cell counts (as described by Sing et al [25] ) and structural properties. Unfortunately, although it has been shown that structural information on the V3 loop may improve predictions [50] , so far no structural information on the V2 loop is available. In addition, other regions of the viral envelope protein should be analyzed. Some of these have already been described to be correlated with tropism [38] , and their incorporation may further improve prediction quality.
